Please log in to view this page
Username
Password
REPRIEVE (A5332) is a large double-blind, randomized, placebo-controlled study of pitavastatin or placebo for about 72 months....
Objectives: Primary: To develop a highly predictive algorithm that identifies TB patients who will be cured by treatment...
HPTN 083 is a study being done to evaluate the efficacy of the long-acting injectable agent, cabotegravir (CAB LA), for...
A5225/HiFLAC is a Phase I/II dose escalation and validation study of the safety, tolerability, and therapeutic effect of an...
The purpose of this study is to determine whether one or two four-month regimens of tuberculosis treatment are as effective as a...
